A Phase 3 interventional study of AXS-05 (dextromethorphan and bupropion) oral tablets in Major Depressive Disorder, Treatment Resistant Depression and Depression, sponsored by Axsome Therapeutics, Inc.. Completed at 51 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-10-12.
Sponsored by Axsome Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc. — 2 open to participants now, 2 under way, 1 of them phase 3. Depressive Disorder, Major · Axsome Therapeutics, Inc..
Among the 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc., this one has the largest enrollment, is one of 2 that started in 2019, is one of 5 in phase 3, and was the 4th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →2 of the 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc. are open now, in 1 country. Recruiting first, the newest first:
Axsome Therapeutics, Inc. · Sites in United States
Ages 18–65
Axsome Therapeutics, Inc. · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2019.
This study's enrollment of 876 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 320 across the 10 interventional studies. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Axsome Therapeutics, Inc. is the lead sponsor of 37 studies on the registry; 12 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
An open-label, long-term, safety study of AXS-05 in patients with major depressive disorder (MDD), including treatment resistant depression.
A multi-center, open-label, long-term study to evaluate the safety and efficacy of AXS-05 in patients with major depressive disorder, including treatment resistant depression, treated for up to one year.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AXS-05 (dextromethorphan and bupropion) oral tablets
Drug page: Dextromethorphan/Bupropion Tablet AXS-05
Oral tablets, taken twice daily for up to 12 months.
Incidence of Treatment-emergent AEs (TEAEs) Following Dosing With AXS-05
Types and rates of adverse events
Time frame: Up to 12 months
| Milestone | AXS-05 |
|---|---|
| Started | 876 |
| Completed | 53 |
| Not completed | 823 |
Types and rates of adverse events
| Participants | AXS-05 |
|---|---|
| Incidence of Treatment-emergent AEs (TEAEs) Following Dosing With AXS-05 | 505 |
Collected over Treatment-emergent adverse events (TEAEs) were AEs with an onset date on or after the date of first dose. TEAEs were collected through 30 days after the last study visit.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AXS-05 | 2/876 (0.2%) | 21/876 (2.4%) | 609/876 (69.5%) |
| Event | AXS-05 |
|---|---|
| Acute myocardial infarctionCardiac disorders | 1/876 |
| Coronary artery diseaseCardiac disorders | 1/876 |
| Left ventricular hypertrophyCardiac disorders | 1/876 |
| Eye inflammationEye disorders | 1/876 |
| NauseaGastrointestinal disorders | 1/876 |
| Chest painGeneral disorders | 1/876 |
| DeathGeneral disorders | 1/876 |
| CholelithiasisHepatobiliary disorders | 1/876 |
| CellulitisInfections and infestations | 1/876 |
| DiverticulitisInfections and infestations | 1/876 |
| Event | AXS-05 |
|---|---|
| DizzinessNervous system disorders | 111/876 |
| NauseaGastrointestinal disorders | 104/876 |
| HeadacheNervous system disorders | 77/876 |
| Dry mouthGastrointestinal disorders | 62/876 |
| Decreased appetiteMetabolism and nutrition disorders | 53/876 |
| NasopharyngitisInfections and infestations | 39/876 |
| Upper respiratory tract infectionInfections and infestations | 35/876 |
| AnxietyPsychiatric disorders | 34/876 |
| DiarrheaGastrointestinal disorders | 33/876 |
| InsomniaPsychiatric disorders | 31/876 |
Overall Safety Population (all subjects who received at least 1 dose of AXS-05)
| Age, Continuous(years) | AXS-05 |
|---|---|
| Mean | 42.5 ± 13.5 |
| Sex: Female, Male(Participants) | AXS-05 |
|---|---|
| Female | 560 |
| Male | 316 |
| Race (NIH/OMB)(Participants) | AXS-05 |
|---|---|
| American Indian or Alaska Native | 3 |
| Asian | 29 |
| Native Hawaiian or Other Pacific Islander | 4 |
| Black or African American | 301 |
| White | 509 |
| More than one race | 10 |
| Unknown or Not Reported | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2019 to primary completion in Oct 2020, 15 months.
Results were first posted in Oct 2022, 1 year 11 months after primary completion. A results delay was requested in Oct 2021.
Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 15 months is below that.
Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dextromethorphan/Bupropion Tablet AXS-05